74 related articles for article (PubMed ID: 8823497)
1. A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Cattan AR; Maung ZT
Cancer Chemother Pharmacol; 1996; 38(6):548-52. PubMed ID: 8823497
[TBL] [Abstract][Full Text] [Related]
2. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
3. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
4. The C.B.17 scid mouse strain as a model for human disseminated leukaemia and myeloma in vivo.
Cattan AR; Douglas E
Leuk Res; 1994 Jul; 18(7):513-22. PubMed ID: 8022201
[TBL] [Abstract][Full Text] [Related]
5. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
7. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
8. Human tumor models in the severe combined immune deficient (scid) mouse.
Paine-Murrieta GD; Taylor CW; Curtis RA; Lopez MH; Dorr RT; Johnson CS; Funk CY; Thompson F; Hersh EM
Cancer Chemother Pharmacol; 1997; 40(3):209-14. PubMed ID: 9219503
[TBL] [Abstract][Full Text] [Related]
9. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype.
Bellamy WT; Mendibles P; Bontje P; Thompson F; Richter L; Weinstein RS; Grogan TM
Cancer Chemother Pharmacol; 1996; 37(4):305-16. PubMed ID: 8548875
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
[TBL] [Abstract][Full Text] [Related]
11. Optimal conditions of chemotherapeutic sensitivity in K562 cell line using tetrazolium dye assay.
Yu D; Yu LL
Zhongguo Yao Li Xue Bao; 1993 Mar; 14(2):137-40. PubMed ID: 8352006
[TBL] [Abstract][Full Text] [Related]
12. Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.
Jordan JP; Hand CM; Markowitz RS; Black P
J Neurooncol; 1992 Sep; 14(1):19-35. PubMed ID: 1335043
[TBL] [Abstract][Full Text] [Related]
13. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
14. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
15. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two cytotoxicity assays--tetrazolium derivative reduction (MTT) and tritiated thymidine uptake--on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs.
Arnould R; Dubois J; Abikhalil F; Libert A; Ghanem G; Atassi G; Hanocq M; Lejeune FJ
Anticancer Res; 1990; 10(1):145-54. PubMed ID: 2334120
[TBL] [Abstract][Full Text] [Related]
18. Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
Li J; Hu XF; Loveland BE; Xing PX
Exp Hematol; 2009 Nov; 37(11):1284-94. PubMed ID: 19703513
[TBL] [Abstract][Full Text] [Related]
19. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells.
Marks DC; Belov L; Davey MW; Davey RA; Kidman AD
Leuk Res; 1992 Dec; 16(12):1165-73. PubMed ID: 1361210
[TBL] [Abstract][Full Text] [Related]
20. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
